TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32934722

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy in patients with high cyclin D1 expression (cN2 stage)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Low cyclin D1 expression group
Number of subjects: 232

Group type: COMPARATOR
Intervention: TPF induction chemotherapy
Number of subjects: 232
Study: 32934758

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in TB patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis of TB and COVID-19
Number of subjects: 0
Study: 32935170

Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL) followed by Alendronate (ALN)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Placebo (PBO) followed by Alendronate (ALN)
Number of subjects: 558
Study: 32935287

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 15 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg/day for 10 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balovaptan 5 mg/day alone for 10 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balovaptan 10 mg/day alone for 10 days
Number of subjects: 16
Study: 32935623

Group type: EXPERIMENTAL
Intervention: Adipose-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32935662

Group type: EXPERIMENTAL
Intervention: Coach-based mobile-enhanced intervention (MEI)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 402
Study: 32935936

Group type: EXPERIMENTAL
Intervention: Weight management intervention over 12 months
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: BMI metrics
Number of subjects: 399
Study: 32936868

Group type: EXPERIMENTAL
Intervention: Total sugar intake (quartile 4 compared to quartile 1)
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Free sugars
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Sugars from milk-based desserts
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Sugars from dairy products
Number of subjects: 101279

Group type: EXPERIMENTAL
Intervention: Sugary drinks
Number of subjects: 101279
Study: 32936948

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays
Number of subjects: 1250
Study: 32936949

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays (e.g., povidone iodine, nitric oxide, GLS-1200 oral spray)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthwashes and nasal sprays (if administered to patients)
Number of subjects: 700
Study: 32938212

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0
Study: 32938232

Group type: EXPERIMENTAL
Intervention: bempegaldesleukin (BEMPEG) plus nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32938465

Group type: EXPERIMENTAL
Intervention: Increased frequency of intentional weight loss attempts of at least five pounds
Number of subjects: 161738
Study: 32938595

Group type: EXPERIMENTAL
Intervention: Healthcare utilisation in people with AD, including rates of AD-associated primary care visits and specialist dermatology referrals, stratified by age, gender, socioeconomic IMD quintile, and ethnicity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prescribing rates across medication classes used in AD (emollients, topical corticosteroids by potency, topical calcineurin inhibitors, topical antimicrobials, antihistamines, oral corticosteroids, and systemic immunomodulatory therapies).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment escalation in people first diagnosed with AD during the study period, analyzed using time-to-event analysis.
Number of subjects: 0
Study: 32939030

Group type: EXPERIMENTAL
Intervention: LAMP3 expression in epithelial cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro studies of LAMP3 expression
Number of subjects: 0
Study: 32939046

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 40
Study: 32939319

Group type: EXPERIMENTAL
Intervention: anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs)
Number of subjects: 7
Study: 32939459

Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 mg plus sofosbuvir 400 mg (daily for 12 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-pregnant reference group (previously enrolled in phase 2 and 3 trials)
Number of subjects: 9
Study: 32939607

Group type: EXPERIMENTAL
Intervention: Crenigacestat 25 mg, administered orally 3 times per week over a 28-day cycle
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Crenigacestat 50 mg, administered orally 3 times per week over a 28-day cycle
Number of subjects: 11
Study: 32940089

Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32940537

Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery System
Number of subjects: 0
Study: 32940955

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for 50 exposure days (~26 weeks)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for a median time of ~4.9 years
Number of subjects: 68
Study: 32941200

Group type: EXPERIMENTAL
Intervention: Urinary neprilysin levels on postoperative day 1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Urinary neprilysin levels at the end of surgery
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Discriminatory power of neprilysin for detecting early AKI
Number of subjects: 96
Study: 32941647

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic transplantation
Number of subjects: 35
Study: 32941876

Group type: EXPERIMENTAL
Intervention: Plasma cadmium levels (58 ng/L median)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Tertiles of plasma cadmium (13, 26, and 39 events of graft failure)
Number of subjects: 672
Study: 32943001

Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy (second trimester)
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Nausea, vomiting, or poor appetite during pregnancy (third trimester)
Number of subjects: 3623
Study: 32943021

Group type: EXPERIMENTAL
Intervention: Pain interference measured via Brief Pain Inventory (London cohort) or Neck Disability Index (Chicago cohort)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pain severity measured using numeric pain rating scale
Number of subjects: 241
Study: 32943047

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment at baseline
Number of subjects: 22125

Group type: COMPARATOR
Intervention: No inhaled corticosteroids (ICS) treatment at baseline
Number of subjects: 22125

Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count ≤ 150 cells/μL
Number of subjects: 22125

Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count 150-300 cells/μL
Number of subjects: 22125

Group type: EXPERIMENTAL
Intervention: Baseline eosinophil count > 300 cells/μL
Number of subjects: 22125
Study: 32943098

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg/month for 7 infusions)
Number of subjects: 13
Study: 32943156

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3488

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3488
Study: 32943160

Group type: EXPERIMENTAL
Intervention: Recommended dosing of DOACs
Number of subjects: 342926

Group type: EXPERIMENTAL
Intervention: Underdosing of DOACs
Number of subjects: 342926

Group type: EXPERIMENTAL
Intervention: Overdosing of DOACs
Number of subjects: 342926

Group type: COMPARATOR
Intervention: Nonrecommended dosing of DOACs (combined underdosing and overdosing)
Number of subjects: 342926
Study: 32943286

Group type: EXPERIMENTAL
Intervention: Molecular T-cell‒mediated rejection (TCMR) scores in TBBs
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Molecular T-cell‒mediated rejection (TCMR) scores in mucosal biopsies
Number of subjects: 457

Group type: COMPARATOR
Intervention: Histologic rejection
Number of subjects: 457

Group type: COMPARATOR
Intervention: Donor-specific antibodies
Number of subjects: 457
Study: 32943410

Group type: EXPERIMENTAL
Intervention: Nintedanib or pirfenidone (censored from survival and progression analyses)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Not applicable (patients not receiving antifibrotic therapy)
Number of subjects: 617
Study: 32943436

Group type: EXPERIMENTAL
Intervention: People with IBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 32943536

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 7639

Group type: EXPERIMENTAL
Intervention: Early HRF
Number of subjects: 7639
Study: 32944251

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (WBV) plus teriparatide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Teriparatide alone
Number of subjects: 35
Study: 32944253

Group type: EXPERIMENTAL
Intervention: Thai version of the foot function index (FFI-Th)
Number of subjects: 49
Study: 32944273

Group type: EXPERIMENTAL
Intervention: Mind the Gap (MTG) intervention delivered by peer coaches over 12 meetings in 18 weeks.
Number of subjects: 9
Study: 32944274

Group type: EXPERIMENTAL
Intervention: Technology-based lifestyle modification program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 10
Study: 32944276

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 50
Study: 32944767

Group type: EXPERIMENTAL
Intervention: Standard ECG recorded at hospital admission
Number of subjects: 431
Study: 32944803

Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Recurrent osteochondral lesion of talus (R-OLT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Primary osteochondral lesion of talus (P-OLT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lateral ankle instability (INST)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Anterior ankle impingement (ANT-IMP)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Posterior ankle impingement (POST-IMP)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combined ankle impingement (COMB-IMP)
Number of subjects: 123
Study: 32945202

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (DP)
Number of subjects: 9
Study: 32945596

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/day for ≥ 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single doses of ethinylestradiol (EE) 30 μg and levonorgestrel (LN) 150 μg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single doses of bupropion (75 mg) and midazolam (2 mg)
Number of subjects: 22
Study: 32945631

Group type: EXPERIMENTAL
Intervention: Elagolix, a novel oral gonadotropin releasing hormone receptor antagonist, indicated for management of moderate-to-severe pain associated with endometriosis
Number of subjects: 0
Study: 32945728

Group type: EXPERIMENTAL
Intervention: Sleep quality and duration interventions, specific details not available
Number of subjects: 0
Study: 32945968

Group type: EXPERIMENTAL
Intervention: AI system-based score ≥ 30
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: RALE score ≥ 12
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Older age, male sex, coronary artery disease, COPD, neurodegenerative disease
Number of subjects: 697
Study: 32946372

Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation
Number of subjects: 16
Study: 32946702

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32946725

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy-naive patients
Number of subjects: 1397
Study: 32946850

Group type: EXPERIMENTAL
Intervention: CT imaging (K-means clustering)
Number of subjects: 5873

Group type: EXPERIMENTAL
Intervention: Emphysema cluster
Number of subjects: 5873

Group type: EXPERIMENTAL
Intervention: Bronchial epithelial gene expression
Number of subjects: 5873

Group type: EXPERIMENTAL
Intervention: Interstitial cluster
Number of subjects: 5873
Study: 32947291

Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 20% albumin with lactated Ringer's solution
Number of subjects: 23
Study: 32947434

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 10
Study: 32947651

Group type: EXPERIMENTAL
Intervention: R-CHOP14 (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days)
Number of subjects: 138
Study: 32948184

Group type: EXPERIMENTAL
Intervention: Baseline log(calcification score)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: log(RANKL)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Previous ischemic cardiomyopathy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Duration of follow up
Number of subjects: 198
Study: 32948202

Group type: EXPERIMENTAL
Intervention: Smokers (with and without COPD)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patients with chronic bronchitis
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 118

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 118
Study: 32948563

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography (POCUS)
Number of subjects: 574
Study: 32948575

Group type: EXPERIMENTAL
Intervention: Hearing loss and vestibular decline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Additional neuropsychological assessments
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cortical auditory-evoked potentials
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: General and disease-specific health-related quality of life
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vestibular decline
Number of subjects: 100
Study: 32948953

Group type: EXPERIMENTAL
Intervention: End-of-life conversation game played in groups of 4-6
Number of subjects: 428
Study: 32948982

Group type: EXPERIMENTAL
Intervention: Open architecture polyetheretherketone (PEEK) interference screw
Number of subjects: 12
Study: 32949123

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT) for 14 weeks
Number of subjects: 33
Study: 32949150

Group type: EXPERIMENTAL
Intervention: Regorafenib treatment
Number of subjects: 30
Study: 32949176

Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg p.o. once every day (days 1-14, with a 21-day cycle)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Oral temozolomide chemotherapy 100 mg/m²
Number of subjects: 1
Study: 32949593

Group type: EXPERIMENTAL
Intervention: Pro-fibrotic M2 macrophage markers
Number of subjects: 0
Study: 32949828

Group type: EXPERIMENTAL
Intervention: Re-biopsy after first line treatment
Number of subjects: 51
Study: 32950058

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Pancreatic islet transplantation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment during kidney transplantation
Number of subjects: 1
Study: 32950075

Group type: EXPERIMENTAL
Intervention: Before lockdown (4 weeks prior)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: After lockdown (4 weeks following)
Number of subjects: 1167
Study: 32950419

Group type: EXPERIMENTAL
Intervention: Prasugrel monotherapy for 3 months
Number of subjects: 201
Study: 32950448

Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Essential hypertension (HTN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Secondary aldosteronism due to Bartter/Gitelman (BG) syndrome
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy subjects (HS)
Number of subjects: 80
Study: 32950749

Group type: EXPERIMENTAL
Intervention: Chronic liver disease (CLD) patients with COVID-19
Number of subjects: 978
Study: 32950785

Group type: EXPERIMENTAL
Intervention: Childhood maltreatment (CMT)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Multiple types of childhood maltreatment (CMT)
Number of subjects: 663
Study: 32950849

Group type: EXPERIMENTAL
Intervention: CYP2C19 status assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32951150

Group type: EXPERIMENTAL
Intervention: Febuxostat (oral doses from 10 to 80 mg)
Number of subjects: 141
Study: 32951151

Group type: EXPERIMENTAL
Intervention: Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Convalescent plasma administered early in the disease course (severe illness group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 38
Study: 32951470

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 37
Study: 32951537

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1445
Study: 32951540

Group type: EXPERIMENTAL
Intervention: Nomogram predicting morbidity
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Multiple symptomatic hemorrhages, initial neurological function after hemorrhage, brainstem location, and associated developmental venous anomaly
Number of subjects: 282
Study: 32951684

Group type: EXPERIMENTAL
Intervention: Personalized dose of fish oil (mean target dose 6.63 g/day to 4.06 g/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dynamic modeling of fish oil dosing
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bayesian design for dosing algorithm
Number of subjects: 46
Study: 32951957

Group type: EXPERIMENTAL
Intervention: ReSinus score prediction for spontaneous conversion to sinus rhythm
Number of subjects: 2426
Study: 32952616

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 84
Study: 32953426

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 2470
Study: 32954239

Group type: EXPERIMENTAL
Intervention: STROKE-CARD care
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2149
Study: 32954238

Group type: EXPERIMENTAL
Intervention: Smartphone application UnityPhilly for naloxone administration
Number of subjects: 112
Study: 32954286

Group type: EXPERIMENTAL
Intervention: Framingham stroke-risk score
Number of subjects: 0
Study: 32954622

Group type: EXPERIMENTAL
Intervention: PEA (Pulmonary Endarterectomy)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: BPA (Balloon Pulmonary Angioplasty)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: All patients (combined treatment)
Number of subjects: 593
Study: 32954946

Group type: EXPERIMENTAL
Intervention: Eye tracking intervention in a visual search paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) intervention
Number of subjects: 0
Study: 32955038

Group type: EXPERIMENTAL
Intervention: CADOT index
Number of subjects: 699

Group type: COMPARATOR
Intervention: BODE index
Number of subjects: 699

Group type: COMPARATOR
Intervention: ADO index
Number of subjects: 699
Study: 32955159

Group type: EXPERIMENTAL
Intervention: Monolithic zirconia crowns
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metal-ceramic crowns
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraoral scanning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control enamel
Number of subjects: 30
Study: 32955176

Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 129
Study: 32955197

Group type: EXPERIMENTAL
Intervention: First course of fecal microbiota transplantation (FMT)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Second course of fecal microbiota transplantation (FMT)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 202
Study: 32955198

Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Lactose ingestion
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Generalized extra-GI symptoms
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Hydrogen and methane breath concentrations
Number of subjects: 2083
Study: 32955488

Group type: EXPERIMENTAL
Intervention: CTLA4 haploinsufficiency (CTLA4h)
Number of subjects: 50
Study: 32955714

Group type: EXPERIMENTAL
Intervention: Usual care plus patient-tailored adherence interventions
Number of subjects: 438

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 438
Study: 32956379

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional transbronchial lung biopsy (TBLB)
Number of subjects: 124
Study: 32956380

Group type: EXPERIMENTAL
Intervention: Consistently low CD4 counts (21%)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Low CD4 counts that increased over time (22%)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Moderate CD4 counts that remained stable (41%)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: High CD4 counts that increased over time (16%)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: ART initiation within 3 months of diagnosis
Number of subjects: 688
Study: 32956407

Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 or 6.0 mg/kg/day
Number of subjects: 23
Study: 32956453

Group type: EXPERIMENTAL
Intervention: Teclistamab (JNJ-64007957)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle and antibody controls
Number of subjects: 0
Study: 32956536

Group type: COMPARATOR
Intervention: Magnesium supplementation
Number of subjects: 735
Study: 32956651

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 23